Overview

A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer

Status:
Recruiting

Trial end date:
2026-03-19

Target enrollment:

Participant gender:

Summary

Single arm phase II study for with primary objective to evaluate the efficacy of PLX038 on response rate for patients with pretreated, metastatic or locally advanced triple negative breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Institut Curie

Collaborator:

ProLynx LLC